Family Medicine & Primary Care Review
eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
2/2025
vol. 27
 
Share:
Send email
Share:
Review paper

Neuraminidase and polymerase inhibitors in the treatment and prevention of influenza in children

Martyna Szwejkowska
1
,
Aneta Nitsch-Osuch
2

  1. Department of Pediatrics with an Observation Unit, Medical University of Warsaw, Warsaw, Poland
  2. Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland
Family Medicine & Primary Care Review 2025; 27(2): 254–264
DOI: https://doi.org/10.5114/fmpcr.2025.149517
Online publish date: 2025/06/27
Article file
- 19 FM&PCR 2 25 - R - Szwejkowska 1654 - Inhibitors.pdf  [0.35 MB]
Get citation
 
PlumX metrics:
 
1. Doniec Z, Mastalerz-Migas A, Jackowska T, et al. ReCOMmendations for the treatment of INFLUENZA in children for Primary care physiciAnS – COMPAS INFLUENZA. Fam Med Prim Care Rev 2019; 21(2): 189–198.
2. Nitsch-Osuch A, Jankowski P, Kokoszka-Paszkot J, et al. Towards better protection of older people against influenza and its complications. Polish recommendations for HD influenza vaccine. Fam Med Prim Care Rev 2024; 26(1): 116–122.
3. Wawryk-Gawda E, Emeryk A, Chojęta A. Differential diagnosis of respiratory viral infections in children in the COVID-19 pandemic time. Fam Med Prim Care Rev 2021; 23(4): 501–507.
4. Flu Vaccines for Children: Centers for Disease Control and Prevention, 2024 [cited 27.04.2024]. Available from URL: https://www.cdc.gov/flu/highrisk/children.html.
5. WHO. Influenza (Seasonal): World Health Organization; 2023 [cited 27.04.2024]. Available from URL: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).
6. Mirowska-Guzel D, Nitsch-Osuch A. Practical tips on vaccination in multiple sclerosis patients. Fam Med Prim Care Rev 2023; 25(2): 217–223.
7. Wang X, Li Y, O’Brien KL, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health 2020; 8(4): e497–e510.
8. Influenza (Flu). Flu News & Spotlights 2023–2024: Centers for Disease Control and Prevention, 2024 [cited 27.04.2024]. Available from URL: https://www.cdc.gov/flu/spotlights/2023-2024/pediatric-flu-deaths.htm.
9. Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis 2020; 39(7): 1201–1208.
10. Liang Y. Pathogenicity and virulence of influenza. Virulence 2023; 14(1): 2223057.
11. Smyk JM, Szydłowska N, Szulc W, et al. Evolution of Influenza Viruses – Drug Resistance, Treatment Options, and Prospects. Int J Mol Sci 2022; 23(20): 12244, doi: 10.3390/ijms232012244.
12. Zaraket H, Hurt AC, Clinch B, el al. Burden of influenza B virus infection and considerations for clinical management. Antiviral Res 2021; 185: 104970.
13. Bai Y, Jones JC, Wong SS, et al. Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance. Viruses 2021; 13(4): 624, doi: 10.3390/v13040624.
14. Ye J, Lin L, Xu J, et al. Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH(2)-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors. Pharmaceuticals (Basel) 2021; 14(4): 371, doi: 10.3390/ph14040371.
15. Shi J, Zeng X, Cui P et al. Alarming situation of emerging H5 and H7 avian influenza and effective control strategies. Emerg Microbes Infect 2023; 12(1): 2155072.
16. Dharmapalan D. Influenza. The Indian Journal of Pediatrics 2020; 87(10): 828–832.
17. Dou D, Revol R, Östbye H, et al. Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. Front Immunol 2018; 9: 1581, doi: 10.3389/fimmu.2018.01581.
18. Ison MG, Hayden FG, Hay AJ, et al. Influenza polymerase inhibitor resistance: Assessment of the current state of the art – A report of the isirv Antiviral group. Antiviral Res 2021; 194: 105158.
19. Govorkova EA, Takashita E, Daniels RS, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020. Antiviral Res 2022; 200: 105281.
20. Świerczyńska M, Mirowska-Guzel DM, Pindelska E. Antiviral Drugs in Influenza. Int J Environ Res Public Health 2022; 19(5): 3018, doi: 10.3390/ijerph19053018.
21. Liu JW, Lin SH, Wang LC, et al. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis. JAMA Netw Open 2021; 4(8): e2119151.
22. Uyeki TM. Oseltamivir Treatment of Influenza in Children. Clin Infect Dis 2018; 66(10): 1501–1503.
23. O’Leary ST, Campbell JD, Ardura MI, et al. Recommendations for Prevention and Control of Influenza in Children, 2023–2024. Pediatrics 2023; 152(4): e2023063773, doi: 10.1542/peds.2023-063773.
24. Prevention CDC. Influenza Antiviral Medications: Summary for Clinicians. 2023 [cited 27.04.2024]. Available from URL: https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.
25. Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 2008; 26: D49–D53.
26. Aranda-Abreu GE, Aranda-Martínez JD, Araújo R, et al. Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol Rep 2020; 72(6): 1538–1541.
27. Yin H, Jiang N, Shi W, et al. Development and Effects of Influenza Antiviral Drugs. Molecules 2021; 26(4): 810.
28. EMA. Tamiflu, Summary of Product Characteristics [cited 27.04.2024]. Available from URL: https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf.
29. Jordie EB, Gibiansky L, Knab T, et al. Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy. Br J Clin Pharmacol 2022; 88(3): 1189–1201.
30. Antoon JW, Sarker J, Abdelaziz A, et al. Trends in Outpatient Influenza Antiviral Use Among Children and Adolescents in the United States. Pediatrics 2023; 152(6): e2023061960, doi: 10.1542/peds.2023-061960.
31. Okubo Y, Uda K, Miyairi I. Trends in Influenza and Related Health Resource Use During 2005–2021 Among Children in Japan. Pediatr Infect Dis J 2023; 42(8): 648–653.
32. FDA. Tamiflu. Highlights of Prescribing Information [cited 27.04.2024]. Available from URL: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information.
33. Bautista F, Engelhard D, Rizzari C, et al. Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children with Influenza. Open Forum Infect Dis 2019; 6(10): ofz430.
34. Walsh PS, Schnadower D, Zhang Y, et al. Association of Early Oseltamivir with Improved Outcomes in Hospitalized Children with Influenza, 2007–2020. JAMA Pediatr 2022; 176(11): e223261.
35. Tejada S, Tejo AM, Peña-López Y, et al. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol 2021; 14(7): 901–918.
36. Malosh RE, Martin ET, Heikkinen T, et al. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis 2018; 66(10): 1492–1500.
37. Rech MA. Oseltamivir for All: Should It Become an Over‐the‐Counter Medication for Influenza Treatment? Pharmacotherapy 2020; 40(3): 182–185.
38. Lyons D, Lauring A. Mutation and Epistasis in Influenza Virus Evolution. Viruses 2018; 10(8): 407.
39. Takahashi E, Sawabuchi T, Kimoto T, et al. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice. J Dairy Sci 2019; 102(11): 9559–9569.
40. FDA. Rapivab (peramivir) Information [cited 27.04.2024]. Available from URL: https://www.fda.gov/drugs/information-drug-class/rapivab-peramivir-information.
41. EMA. Alpivab. Summary of product characteristics [cited 27.04.2024]. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/alpivab.
42. FDA. Peramivir, Clinical pharmacology review (Efficacy supplement) [cited 27.04.2024]. Available from URL: https://www.fda.gov/media/146359/download.
43. Scott LJ. Peramivir: A Review in Uncomplicated Influenza. Drugs 2018; 78(13): 1363–1370.
44. Xu M, Cai T, Yue T, et al. Comparative effectiveness of oseltamivir versus peramivir for hospitalized children (aged 0–5 years) with influenza infection. Int J Infect Dis 2023; 128: 157–165.
45. Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther 2012; 10(2): 123–143, doi: 10.1586/eri.11.174.
46. FDA. Rapivab, Prescribing Information [cited 27.04.2024]. Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf.
47. FDA. Relenza (zanamivir) Information [cited 27.04.2024]. Available from URL: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/relenza-zanamivir-information.
48. EMA. Summary of product characteristics [cited 27.04.2024]. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/dectova.
49. FDA. Relenza, Highlights of prescribing information [cited 27.04.2024]. Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021036s025lbl.pdf.
50. EMC. Relenza [cited 27.04.2024]. Available from URL: https://www.medicines.org.uk/emc/product/3809/smpc.
51. Agency AsNS. Relenza – The First Effective Flu-Fighter [cited 27.04.2024]. Available from URL: https://www.csiro.au/en/research/health-medical/vaccines/relenza.
52. Denel-Bobrowska M, Olejniczak AB. Non-nucleoside structured compounds with antiviral activity-past 10 years (2010–2020). Eur J Med Chem 2022; 231: 114136.
53. Shirley M. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza. Drugs 2020; 80(11): 1109–1118.
54. Koshimichi H, Ishibashi T, Wajima T. Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients. J Pharm Sci 2019; 108(9): 3112–3117.
55. Kim Y, Lee S, Kim Y, et al. Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects. Clin Transl Sci 2022; 15(2): 422–432, doi: 10.1111/cts.13160.
56. EMA. Xofluza. Summary of product characteristics [cited 27.04.2024]. Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/xofluza.
57. Baker JB, Block SL, Cagas SE, et al. Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study. Pediatr Infect Dis J 2023; 42(11): 983–989.
58. Watanabe A, Ishida T, Hirotsu N, et al. Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study. Antiviral Res 2019; 163: 75–81.
59. O’Hanlon R, Shaw ML. Baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol 2019; 35: 14–18.
60. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018; 379(10): 913–923.
61. Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020; 20(10): 1204–1214.
62. Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med 2020; 383(4): 309–320.
63. Baker J, Block SL, Matharu B, et al. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children. Pediatr Infect Dis J 2020; 39(8): 700–705.
64. EMA. Xofluza. Highlights of Prescribing Information [cited 27.04.2024]. Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210854s001lbl.pdf.
65. Roosenhoff R, Reed V, Kenwright A, et al. Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). Clin Infect Dis 2020; 71(5): 1186–1194.
66. Jones JC, Yen H-L, Adams P, et al. Influenza antivirals and their role in pandemic preparedness. Antiviral Res 2023; 210: 105499.
67. Li J, Wagatsuma K, Sun Y, et al. Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014–2019/2020 seasons in Japan: an observational study. BMC Infect Dis 2023; 23(1): 188.
68. Patel P, Laurich VM, Smith S, et al. Point-of-Care Influenza Testing in the Pediatric Emergency Department. Pediatr Emerg Care 2020; 36(11): 515–518.
69. Kitt E, Drew RJ, Cunney R, et al. Diagnosis and Management of Pediatric Influenza in the Era of Rapid Diagnostics. J Pediatric Infect Dis Soc 2020; 9(1): 51–55.
70. Antoon JW, Hall M, Feinstein JA, et al. Guideline-Concordant Antiviral Treatment in Children at High Risk for Influenza Complications. Clin Infect Dis 2023; 76(3): e1040–e1046.
Copyright: © 2025 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.